Ocrelizumab Superior for Delaying Disability Progression in Primary Progressive MS

MONDAY, June 1, 2026 -- For patients with primary progressive multiple sclerosis (PPMS), ocrelizumab is superior for delaying disability progression, according to a study published in the May 30 issue of The Lancet.
Gavin Giovannoni, M.D., from the...